MGMT and neoplasm: Most patients underwent surgery until 2021; the cases have been reviewed to identify only glioblastoma IDH wild-type patients (GBM, grade 4, according to 2021 CNS5 tumor classification); in 53 out of 93 cases (57%), the MGMT promoter was methylated whereas it was unmethylated in the remaining 40 patients (43%).